You have read all your free articles, to continue reading subscribe to read the rest of this content.
The company has anounced results from PIONEER 2, the second phase 3a trial with oral semaglutide for treatment of adults with type 2 diabetes. Oral semaglutide is a new GLP-1 analogue taken once daily as a tablet. The 52-week, open label trial investigated the efficacy and safety of 14 mg…
Orexo has acquired the exclusive US rights to GAIA AG´s (GAIA) deprexis, a digital therapy to help patients manage their symptoms of depression. The announcement follows two earlier agreements with GAIA where Orexo acquired the exclusive US commercial rights to vorvida which has been proven to rAlready a subscriber Login…
AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. The approval by the Food and DrAlready a subscriber Login You have read all…
LEO Pharma and Korean JW Pharmaceutical have announced that LEO Pharma has filed an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for a pharmacokinetics study in the US. The filing is based on the two companies’ ongoing collaboration on the development Already a subscriber…
